Celtic Pours More Private Equity Into The Promise Of Antibody-Drug Conjugates
This article was originally published in Start Up
Celtic Therapeutics will put as much as $50 million into ADC Therapeutics to develop next-generation cancer drugs based on assets from Spirogen, another of its other portfolio companies.
You may also be interested in...
Previously partnered with Teva on a small molecule drug conjugate, biotech says its focus going forward will be on developing ADCs, with partners and in-house.